Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study
- 1 December 2018
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 77 (12) , 1750-1756
Abstract
Objective Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in older people. Contemporary estimates of the incidence and prevalence are lacking, and no previous study has assessed treatment patterns at a population level. This study aims to address this. Methods We extracted anonymised electronic medical records of patients over the age of 40 years from the Clinical Practice Research Datalink in the period 1990–2016. The absolute rate of PMR per 100 000 person-years was calculated and stratified by age, gender and calendar year. Incidence rate ratios were calculated using a Poisson regression model. Among persons with PMR, continuous and total duration of treatment with glucocorticoids (GC) were assessed. Results 5 364 005 patients were included who contributed 44 million person-years of follow-up. 42 125 people had an incident diagnosis of PMR during the period. The overall incidence rate of PMR was 95.9 per 100 000 (95% CI 94.9 to 96.8). The incidence of PMR was highest in women, older age groups and those living in the South of England. Incidence appears stable over time. The prevalence of PMR in 2015 was 0.85 %. The median (IQR) continuous GC treatment duration was 15.8 (7.9–31.2) months. However, around 25% of patients received more than 4 years in total of GC therapy. Conclusions The incidence rates of PMR have stabilised. This is the first population-based study to confirm that a significant number of patients with PMR receive prolonged treatment with GC, which can carry significant risks. The early identification of these patients should be a priority in future research.Keywords
Funding Information
- Programme Grants for Applied Research (NIHR-RP-2014-04-026)
This publication has 26 references indexed in Scilit:
- 2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiativeArthritis & Rheumatism, 2012
- Prevention and treatment of systemic glucocorticoid side effectsInternational Journal of Dermatology, 2010
- The prevalence of 30 ICD-10 autoimmune diseases in DenmarkImmunologic Research, 2010
- Epidemiology of giant cell arteritis and polymyalgia rheumaticaArthritis Care & Research, 2009
- Dose-related patterns of glucocorticoid-induced side effectsAnnals of the Rheumatic Diseases, 2009
- Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcomeFamily Practice, 2008
- Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001Annals of the Rheumatic Diseases, 2006
- Adverse effects of oral corticosteroids in relation to dose in patients with lung diseaseThorax, 2001
- Epidemiology of polymyalgia rheumatica in olmsted county, minnesota, 1970–1991Arthritis & Rheumatism, 1995
- Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern ItalyArthritis & Rheumatism, 1991